



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/931,449	08/16/2001	Santosh S. Arcot	215063.02901.	2650

35617 7590 11/30/2004

DAFFER MCDANEIL LLP
P.O. BOX 684908
AUSTIN, TX 78768

EXAMINER

LU, FRANK WEI MIN

ART UNIT	PAPER NUMBER
----------	--------------

1634

DATE MAILED: 11/30/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/931,449	Applicant(s) ARCOT, SANTOSH S.	
	Examiner Frank W Lu	Art Unit 1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 21 July 2004.
- 2a) ☒ This action is FINAL. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 3,5-29,35 and 36 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 3,5-29,35 and 36 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 16 August 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ 6) ☐ Other: _____

DETAILED ACTION

Response to Amendment

1. Applicant's response to the office action filed on July 21, 2004 has been entered. The claims pending in this application are claims 3, 5-29, 35, and 36. Rejection and/or objection not reiterated from the previous office action are hereby withdrawn in view of the amendment filed on July 21, 2004.

Specification

2. Since applicant has filed a clean copy of substitute specification on November 24, 2004, the substitute specification has been entered.

Claim Objections

3. Claim 10 is objected to because of the following informality: "a presence of the microsphere-bound ligated products" in step (d) should be "the presence of microsphere-bound ligated products"

Appropriate correction is required.

Claim Rejections - 35 USC § 112

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1634

5. Claims 5, 6, 10-29, 35, and 36 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

6. Claim 5 is rejected as vague and indefinite. Since, in claim 5, a first subset of one or more subsets of free probes is specific for the first portion of the one or more first target nucleic acid sequences and a second subset of free probes (ie., the first oligonucleotide in the second oligonucleotide probe sets) is specific for the first portion of the one or more second target nucleic acid sequences, the one subset which has substantially identical nucleotide sequence that are specific for the second portion of the one or more first and second target nucleic acid sequences in the last part of the claim should not be one subset of free probe. Please clarify.

7. Claim 10 is rejected as vague and indefinite in view of the phrase "the microspheres of different subsets of the at least one subset of bound probes" in (iii) of step (a). Since, according to (ii) of step (a), the bound probes of the at least one subset of bound probes comprise a microsphere and an oligonucleotide, it is unclear how at least one subset of bound probes have different subsets of the microspheres. Please clarify.

8. Claims 15 and 22 are rejected as vague and indefinite because the phrase "the at least one subset of bound probes comprises at least two subsets of bound probes". It is unclear how one subset of bound probes can comprise at least two subsets of bound probes. Please clarify.

9. Claims 17, 20 and 24 are rejected as vague and indefinite because the phrase "the at least one subset of free probes comprises at least two subsets of free probes". It is unclear how one subset of free probes can comprise at least two subsets of free probes. Please clarify.

Art Unit: 1634

10. Claim 23 is rejected as vague and indefinite because it is unclear that other portion of the oligonucleotides of the at least two subsets of bound probes locates on the 3' ends of the oligonucleotides or not. Please clarify.

Claim Rejections - 35 USC § 102

11. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

12. Claims 3, 7, and 9 are rejected under 35 U.S.C. 102(e) as being anticipated by Barany *et al.*, (US 2003/0022182 A1, priority date: February 9, 1996).

Barany *et al.*, teach detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays.

Regarding claim 3, since Barany *et al.*, teach a method for identifying one or more of a plurality of sequences differing by one or more single-base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences comprising: providing a sample potentially containing one or more target nucleotide sequences with a plurality of sequence differences; providing a plurality of oligonucleotide probe sets, each set characterized by (a) a first oligonucleotide probe, having a target-specific portion and an addressable array-specific portion, and (b) a second oligonucleotide probe, having a target-specific portion and a detectable reporter label, wherein the oligonucleotide probes in a particular set are suitable for ligation

Art Unit: 1634

together when hybridized adjacent to one another on a corresponding target nucleotide sequence, but have a mismatch which interferes with such ligation when hybridized to any other nucleotide sequence present in the sample; providing a ligase, blending the sample, the plurality of oligonucleotide probe sets, and the ligase to form a mixture; subjecting the mixture to one or more ligase detection reaction cycles comprising a denaturation treatment, wherein any hybridized oligonucleotides are separated from the target nucleotide sequences, and a hybridization treatment, wherein the oligonucleotide probe sets hybridize at adjacent positions in a base-specific manner to their respective target nucleotide sequences, if present in the sample, and ligate to one another to form a ligated product sequence containing (a) the addressable array-specific portion, (b) the target-specific portions connected together, and (c) the detectable reporter label, and, wherein the oligonucleotide probe sets may hybridize to nucleotide sequences in the sample other than their respective target nucleotide sequences but do not ligate together due to a presence of one or more mismatches and individually separate during the denaturation treatment; providing a solid support with different capture oligonucleotides immobilized at particular sites, wherein the capture oligonucleotides have nucleotide sequences complementary to the addressable array-specific portions; contacting the mixture, after said subjecting, with the solid support under conditions effective to hybridize the addressable array-specific portions to the capture oligonucleotides in a base-specific manner, thereby capturing the addressable array-specific portions on the solid support at the site with the complementary capture oligonucleotide; and detecting the reporter labels of ligated product sequences captured to the solid support at particular sites, thereby indicating the presence of one or more target nucleotide sequences in the sample (see page 34, claim 1), Barany *et al.*, disclose contacting a sample suspected of containing one or more target nucleic acid sequences with one or more subset of free probes and

Art Unit: 1634

one or more subsets of spectrally-addressable bound probes (ie., one or more set of the first and second oligonucleotide probes); allowing the one or more subsets of free probes and the one or more subsets of spectrally-addressable bound probes to hybridize to the one or more target nucleic acid sequences, if present in the sample; ligating the hybridized free probes with the hybridized spectrally-addressable bound probes, wherein a free probe hybridized to a target nucleic acid sequence is ligated with a spectrally-addressable bound probe hybridized to the same target nucleic acid sequence, to provide spectrally-addressable ligated products; and detecting a presence of the spectrally-addressable ligated products, analyzing the target nucleic acid sequences of the spectrally-addressable ligated products, or performing said detecting and said analyzing as recited in claim 3. Since Barany *et al.*, teach one or more target nucleotide sequences with a plurality of sequence differences (see page 34, claim 1), according to the definition in the specification (see page 9), “substantially identical” means that, when used in connection with the phrase nucleotide sequence, “one or more nucleotides at one or more positions of probes in a subset may differ due to one or more substitutions, insertions, deletions, or combinations thereof but can still be distinguished from probes belonging to another subset and can substantially hybridize to the correct position on the target molecule,” Barany *et al.*, disclose that the first portions of the first and second target nucleic acids in one or more target nucleic acids sequences recited in claim 3 are distinguishable while the second portions of the first and second target nucleic acids in one or more target nucleic acids sequences recited in claim 3 are substantially identical. Since Barany *et al.*, teach a plurality of oligonucleotide probe sets, each set characterized by a first oligonucleotide probe and a second oligonucleotide (see page 34, claim 1), Barany *et al.*, disclose that a first subset of one or more subsets of spectrally addressable bound probes (ie., the first oligonucleotide in the first oligonucleotide probe sets) is

Art Unit: 1634

specific for the first portion of the one or more first target nucleic acid sequences and a second subset of one or subsets of spectrally addressable bound probes (ie., the first oligonucleotide in the second oligonucleotide probe sets) is specific for the first portion of the one or more second target nucleic acid sequences as recited in claim 3. According to the definition of “substantially identical” in the specification (see page 9), Barany *et al.*, teach that one or more subsets of free probes (ie., the second oligonucleotide probes in a plurality of oligonucleotide probe sets) have substantially identical nucleotide sequence that are specific for the second portion of the one or more first and second target nucleic acid sequences as recited in claim 3.

Regarding claim 7, the ligase taught by Barany *et al.*, is considered to be thermostable (see page 34, claim 1) since the ligation reaction is performed in a certain temperature in order to maximize the activity of the ligase.

Regarding claim 9, Barany *et al.*, teach contacting the sample with polymerase chain reaction components and amplifying the one or more target nucleic acid sequences (see Figures 8 and 9).

Therefore, Barany *et al.*, teach all limitations recited in claims 3, 7, and 9.

13. Claim 5 is rejected under 35 U.S.C. 102(e) as being anticipated by Barany *et al.*, (US 2003/0032016 A1, priority date: May 29, 1996).

Barany *et al.*, teach detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays.

Regarding claim 5, Barany *et al.*, teach a method for identifying one or more of a plurality of sequences differing by one or more single-base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences comprising: providing a sample

Art Unit: 1634

potentially containing one or more target nucleotide sequences with a plurality of sequence differences; providing one or more oligonucleotide probe sets, each set characterized by (a) a first oligonucleotide probe, having a target-specific portion and a 5' upstream primer-specific portion and (b) a second oligonucleotide probe, having a target-specific portion and a 3' downstream primer-specific portion, wherein the oligonucleotide probes in a particular set are suitable for ligation together when hybridized adjacent to one another on a corresponding target nucleotide sequence, but have a mismatch which interferes with such ligation when hybridized to any other nucleotide sequence present in the sample; providing a ligase; blending the sample, the plurality of oligonucleotide probe sets, and the ligase to form a ligase detection reaction mixture; subjecting the ligase detection reaction mixture to one or more ligase detection reaction cycles comprising a denaturation treatment, wherein any hybridized oligonucleotides are separated from the target nucleotide sequences, and a hybridization treatment, wherein the oligonucleotide probe sets hybridize at adjacent positions in a base-specific manner to their respective target nucleotide sequences, if present in the sample, and ligate to one another to form a ligation product sequence containing (a) the 5' upstream primer-specific portion, (b) the target-specific portions connected together, and (c) the 3' downstream primer-specific portion with the ligation product sequence for each set being distinguishable from other nucleic acids in the ligase detection reaction mixture, and, wherein the oligonucleotide probe sets may hybridize to nucleotide sequences in the sample other than their respective target nucleotide sequences but do not ligate together due to a presence of one or more mismatches and individually separate during the denaturation treatment; providing one or a plurality of oligonucleotide primer sets, each set characterized by (a) an upstream primer containing the same sequence as the 5' upstream primer-specific portion of the ligation product sequence and (b) a downstream primer complementary to the 3'

Art Unit: 1634

downstream primer-specific portion of the ligation product sequence, wherein one of the primers has a detectable reporter label; providing a polymerase; blending the ligase detection reaction mixture with the one or a plurality of oligonucleotide primer sets, and the polymerase to form a polymerase chain reaction mixture; subjecting the polymerase chain reaction mixture to one or more polymerase chain reaction cycles comprising a denaturation treatment, wherein hybridized nucleic acid sequences are separated, a hybridization treatment, wherein the primers hybridize to their complementary primer-specific portions of the ligation product sequence, and an extension treatment, wherein the hybridized primers are extended to form extension products complementary to the sequences to which the primers are hybridized, wherein, in a first cycle, the downstream primer hybridizes to the 3' downstream primer-specific portion of the ligation product sequence and extends to form an extension product complementary to the ligation product sequence, and, in subsequent cycles, the upstream primer hybridizes to the 5' upstream primer-specific portion of the extension product complementary to the ligation product sequence and the 3' downstream primer hybridizes to the 3' downstream portion of the ligation product sequence; detecting the reporter labels; and distinguishing the extension products to indicate the presence of one or more target nucleotide sequences in the sample (page 44, claim 1), Barany *et al.*, disclose contacting a sample suspected of containing one or more target nucleic acid sequences with one or more subset of free probes and one or more subsets of spectrally-addressable bound probes (ie., one or more set of the first and second oligonucleotide probes); allowing the one or more subsets of free probes and the one or more subsets of spectrally-addressable bound probes to hybridize to the one or more target nucleic acid sequences, if present in the sample; ligating the hybridized free probes with the hybridized spectrally-addressable bound probes, wherein a free probe hybridized to a target nucleic acid sequence is

Art Unit: 1634

ligated with a spectrally-addressable bound probe hybridized to the same target nucleic acid sequence, to provide spectrally-addressable ligated products; and detecting a presence of the spectrally-addressable ligated products, analyzing the target nucleic acid sequences of the spectrally-addressable ligated products, or performing said detecting and said analyzing as recited in claim 5. Since Barany *et al.*, teach one or more target nucleotide sequences with a plurality of sequence differences (see page 34, claim 1), according to the definition in the specification (see page 9), “substantially identical” means that, when used in connection with the phrase nucleotide sequence, “one or more nucleotides at one or more positions of probes in a subset may differ due to one or more substitutions, insertions, deletions, or combinations thereof but can still be distinguished from probes belonging to another subset and can substantially hybridize to the correct position on the target molecule,” Barany *et al.*, disclose that the first portions of the first and second target nucleic acids in one or more target nucleic acids sequences recited in claim 5 are distinguishable while the second portions of the first and second target nucleic acids in one or more target nucleic acids sequences recited in claim 5 are substantially identical. Since Barany *et al.*, teach a plurality of oligonucleotide probe sets, each set characterized by a first oligonucleotide probe and a second oligonucleotide (see page 44, claim 1), Barany *et al.*, disclose that a first subset of one or more subsets of free probes (ie., the first oligonucleotide in the first oligonucleotide probe sets) is specific for the first portion of the one or more first target nucleic acid sequences and a second subset of free probes (ie., the first oligonucleotide in the second oligonucleotide probe sets) is specific for the first portion of the one or more second target nucleic acid sequences as recited in claim 5. According to the definition of “substantially identical” in the specification (see page 9), Barany *et al.*, teach that one subset of spectrally addressable bound probes (ie., the second oligonucleotide probes in a

Art Unit: 1634

plurality of oligonucleotide probe sets) has substantially identical nucleotide sequence that are specific for the second portion of the one or more first and second target nucleic acid sequences as recited in claim 5.

Therefore, Barany *et al.*, teach all limitations recited in claim 5.

14. Claims 10-14, 22, 25, 26, 29, 35, and 36 are rejected under 35 U.S.C. 102(e) as being anticipated by Chee *et al.*, (US Patent No. 6,355,431, priority date: April 20, 1999).

Claim 10 is rejected in view of the ambiguity of claim 10 (see above rejections under 35 USC 112, second paragraph).

Regarding claim 10, as shown in Figures 7A to 7F, Chee *et al.*, teach: (a) contacting a sample, which is suspected of containing target nucleic acid molecules, with a mixture comprising at least one subset of free probes (ie., a second OLA primer 50) and at least one subset of bound probes (ie., a first OLA primer 45), wherein (i) the free probes of the at least one subset of free probes comprise two opposing ends, wherein a detectable label is at a first of the two opposing ends (ie., see column 11, last paragraph for the original primer with a fluorescent label) and a nucleotide at a second of two opposing ends, and wherein the free probes of the at least one subset of free probes further comprising an oligonucleotide having a predetermined nucleotide sequence that is complementary to at least a first portion of the target nucleic acid molecules (see Figure 7B); (ii) the bound probes of the at least one subset of bound probes comprise a microsphere and an oligonucleotide probe wherein the oligonucleotide probes comprise an oligonucleotide at a first end of the oligonucleotide probes having a modifier moiety (ie., amino groups, see column 43, last paragraph bridging to column 44, first paragraph) which is used for coupling the oligonucleotide probe to the microsphere (see column 43) and wherein

Art Unit: 1634

the oligonucleotide probe further comprises an oligonucleotide having a predetermined nucleotide sequence that is complementary to at least another portion of the target nucleic acid molecules (see Figure 7B); and (iii) the microspheres of bound probes of the least one subset of bound probes having an unique spectral address or an unique fluorescence dye which allows one to distinguish the microspheres of different subsets of the at least one subset of bound probes (see columns 44 and 45); (b) allowing the free probes and the bound probes to hybridize to the target nucleic acid molecules (ie., see Figure 7B); (c) ligating one end of the oligonucleotides of the hybridized free probes with one end of the oligonucleotides of the bound probes to provide microsphere-bound ligated products (see Figure 7C); and (d) detecting the presence of microsphere-bound ligated products (see Figures 7D to 7F, and column 6, last paragraph bridging to column 7, first paragraph).

Regarding claims 11 and 12, since the free probes and bound probes bind to different region of the target nucleic acids (see Figures 7A to 7F), Chee *et al.*, teach claims 11 and 12.

Regarding claims 13, 14, and 22, as shown in Figures 7A, 7B, 7C, and 7D, since the second OLA primer 50 (free probe) is 3' of the first OLA primer 45 and 3' -OH of the first OLA primer 45 ligates with phosphate group of the second OLA primer 50 in the presence of a DNA ligase (see attachment in previous office action) to form a 3', 5' phosphodiester bond, Chee *et al.*, teach that the free probe comprises a phosphate at one end of the oligonucleotide of the free probe (5' end of the second OLA primer 50). Since 5' end the second OLA primer 50 (free probe) is used for the ligation reaction and its fluorescence label must be in its 3' end and the first OLA primer 45 with modified moiety comprising an primary amino group (see columns 43 and 44), Chee *et al.*, teach claim 22 because the phrase "which couples the 5' end of the oligonucleotide of the bound probe to a carboxylic acid group on the microsphere" is only

Art Unit: 1634

considered as an ability of the modified moiety. Since 5' of the first OLA primer 45 has a phosphate, claim 14 is anticipated by Chee *et al.*

Regarding claims 25, 26, and 29, since Chee *et al.*, teach that, after the ligation, the immobilized ligated oligonucleotide is denatured to remove the target nucleic acid and then distribute on an array. Finally the immobilized ligated oligonucleotide (modified primer nucleic acid) is detected (see lines 33-47 in column 3). Since above ligation and detection are carried out in a separate reaction vessel, Chee *et al.*, teach claim 26. Alternatively, since Chee *et al.*, teach that, after the ligation, the mixtures is added a second enzyme, a polymerase such that the circular probe is amplified in a rolling circle amplification (RCA) assay (see lines 58-65 in column 3). Since, in the alternative assay, ligation and detection are carried out in a single reaction vessel, Chee *et al.*, teach claims 25 and 29.

Regarding claims 35 and 36, since the microsphere includes amino groups including aliphatic and aromatic amines (see lines 65-67 in column 43 and lines 1-3 in column 44), Chee *et al.*, teach the bound probe comprising a microsphere with a modified moiety wherein the modified moiety comprises an primary amino group as recited in claims 35 and 36.

Therefore, Chee *et al.*, teach all limitations recited in claims 10-14, 22, 25, 26, 29, 35, and 36.

Response to Arguments

In page 11, second paragraph bridging to page 12, last paragraph of applicant's remarks, applicant argues that "[C]hee does not teach contacting the target nucleic acid with a spectrally-addressable bound probe".

This argument has been fully considered but it is not persuasive toward the withdrawal of the rejection. As shown in Figures 1A to 1C and Figures 7A to 7F, since OLA primer 45 is

Art Unit: 1634

bound to a microsphere 10, the OLA primer 45 is a bound probe. Since Chee *et al.*, teach that the microsphere further comprises an optical signature such as a fluorescent dye (see columns 44 and 45), Chee *et al.*, do teach contacting the target nucleic acid with a spectrally-addressable bound probe (ie., the OLA primer 45).

Claim Rejections - 35 USC § 103

15. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

16. Claim 6 is rejected under 35 U.S.C. 103(a) as being unpatentable over Barany *et al.*, (May 29, 1996) as applied to claim 5 above, and further in view of Kwok *et al.*, (US Patent No. 5,945,283, published on August 31, 1999).

The teachings of Barany *et al.*, have been summarized previously, *supra*.

Barany *et al.*, do not disclose that the assay is performed in a first and a second reaction vessel, wherein a first portion of the sample is contacted with the first subset of free probes in the first reaction vessel and wherein a second portion of the sample is contacted with the second subset of free probes in the second reaction vessel as recited in claim 6.

Kwok *et al.*, teach to test two nucleic acid samples in separate reaction vessels (see column 5, third paragraph).

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to have performed the assay recited in claim 5 in a first and a second reaction vessel wherein a first portion of the sample is contacted with the first subset of

Art Unit: 1634

free probes in the first reaction vessel and a second portion of the sample is contacted with the second subset of free probes in the second reaction vessel in view of the prior art of Barany *et al.*, and Kwok *et al.*. One having ordinary skill in the art would have been motivated to do so because Kwok *et al.*, have successfully test two nucleic acid samples in separate reaction vessels and performing the assay recited in claim 5 in separate reaction vessels would enhance to use a single sample for multiple purposes and save laboratory cost. One having ordinary skill in the art at the time the invention was made would have been a reasonable expectation of success to perform the assay recited in claim 5 in separate reaction vessels.

17. Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over as applied to Barany *et al.*, (February 9, 1996) as applied to claims 3, 7, and 9 above, and further in view of Church *et al.*, (US Patent No. 6,485,944 B1, filed on March 12, 1999).

The teachings of Barany *et al.*, have been summarized previously, *supra*.

Barany *et al.*, do not disclose that each of spectrally-addressable bound probes in the first subset comprise a first amount of at least one fluorescent dye, wherein each of the spectrally-addressable bound probes in the second subset probes in the second subset comprise a second amount of the at least one fluorescent dye, wherein the first amount is different than the second amount, and wherein the first subset and second subset are distinguishable based at least on the first and second amounts as recited in claim 8. However, Barany *et al.*, perform ligated chain reactions using spectrally-addressable bound probes wherein each of the spectrally-addressable bound probes has a distinguishable fluorescent dye (see Figure 8 and [0096] in pages 8 and 9).

Church *et al.*, teach that, when a first and a second nucleic acid probes are labeled with a first and a second fluorescent dyes, the relative amount of the first fluorescent dye and the

Art Unit: 1634

second fluorescent dye is used to detect the amount of a RNA expression in a first RNA-containing nucleic acid population relative to that expressed in a second RNA-containing nucleic acid population (see column 2, fifth paragraph).

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to have performed the method recited in claim 3 wherein each of spectrally-addressable bound probes in the first subset comprise a first amount of at least one fluorescent dye, wherein each of the spectrally-addressable bound probes in the second subset probes in the second subset comprise a second amount of the at least one fluorescent dye, wherein the first amount is different than the second amount, and wherein the first subset and second subset are distinguishable based at least on the first and second amounts in view of the prior art of Barany *et al.*, and Church *et al.*. One having ordinary skill in the art would have been motivated to do so because Church *et al.*, have successfully detected relative amount of two nucleic acids using the relative amount of the first fluorescent dye and the second fluorescent dye (see Church *et al.*, column 2, fifth paragraph) and the simple replacement of one well known fluorescence detection method (i.e., the method taught by Barany *et al.*,) from another well known fluorescence detection method (i.e., using the relative amount of the first fluorescent dye and the second fluorescent dye by Church *et al.*,) during the process of performing the method recited claim 3 would have been, in the absence of convincing evidence to the contrary, *prima facie* obvious to one having ordinary skill in the art at the time the invention was made because the fluorescence detection method taught by Barany *et al.*, and the fluorescence detection method taught by Church *et al.*, are functional equivalent methods which are used for the same purpose (ie., detection of nucleic acid hybridization).

Art Unit: 1634

Furthermore, the motivation to make the substitution cited above arises from the expectation that the prior art elements will perform their expected functions to achieve their expected results when combined for their common known purpose. Support for making the obviousness rejection comes from the M.P.E.P. at 2144.06.

Response to Arguments

18. Applicant's arguments with respect to claims 6 and 8 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

19. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

20. No claim is allowed.

Art Unit: 1634

21. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is either (703)872-9306 or (703)305-3014.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (571)272-0745.

Any inquiry of a general nature or relating to the status of this application should be directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196.

Frank Lu
PSA
November 24, 2004


W. Gary Jones
Supervisory Patent Examiner
Technology Center 1600